Skip to main content
Clinical Trials/IRCT20200823048493N1
IRCT20200823048493N1CompletedPhase 3

The effect of adding magnesium supplement on depressive symptoms in patients with major depressive disorder treated with antidepressants (SSRI

Ahvaz University of Medical Sciences0 sites48 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
48

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 70 years (—)
Sex
All

Inclusion Criteria

  • Patients with major depression based on DSM-S and according to the diagnosis of a psychiatrist
  • Age over 18 years
  • Having minimum education to read the questionnaire

Exclusion Criteria

  • Neurological disorders
  • Taking alcohol and drug use during the last 6 months
  • Active suicidal thoughts
  • Pregnancy and lactation
  • Mental retardation
  • Liver and kidney failure
  • Receiving monooxidase inhibitors during the last 8 weeks
  • History of seizures
  • Taking magnesium-interfering drugs
  • Presence of uncontrolled diseases such as diabetes and high blood pressure
  • Allergy to antidepressants or magnesium supplements

Investigators

Similar Trials